Neuropsychological Evaluation of Psychiatric and Neurological Patients

Schizophrenia Clinical Trial

Official title:

Neuropsychological Evaluation of Psychiatric and Neurological Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00001192
• Other study ID #: 830176
• Secondary ID: 83-M-0176
• Status: Completed
• Phase: N/A
• First received: November 3, 1999
• Last updated: June 30, 2017
• Start date: October 18, 1983
• Est. completion date: December 20, 2006

Study information

• Verified date: December 20, 2006
• Source: National Institutes of Health Clinical Center (CC)
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study will allow researchers to use various types of tests to evaluate cognitive and sensory functions. These tests, referred to as "batteries" will evaluate attention, executive functions, general intellectual functioning, language, memory, motor functions, orientation, personality, selected sensory and perceptual functions, vigilance (alertness), and visual-spatial functions. Children and adult patient will receive different test batteries.

The goals of this research study are to;

1. Create descriptions based on the performance of each patient on the test batteries. Then use this information to relate patient behavior to their neurophysiological, neuroradiological, and biochemical descriptions.

2. Define subgroups of patients based on their neurobehavior in order to decrease the variability of psychiatric diagnoses, treatments, and prognoses.

Description:

Neuropsychological tests are used to provide an assessment of cognitive functions in patients with idiopathic generalized epileptic (IGE) disorders and their first-degree relatives. The battery comprises tests designed to tap attention, memory, selected sensory and perceptual functions, vigilance, and visual-spatial functions. Modified batteries have been developed for the assessment of children ages 5-8, and children ages 8-16. The data provided by these batteries are compared with genetic profiles of the same participants that have been ascertained from blood samples analyzed by colleagues at the Mount Sinai School of Medicine/Columbia University in New York City.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4300
• Est. completion date: December 20, 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A to 95 Years

Eligibility

• INCLUSION CRITERIA:

Patients.

Normal volunteers.

EXCLUSION CRITERIA:

Subjects over 95 years of age.

Subjects with a history of alcohol or drug abuse, psychopathology, or central nervous system pathology, other than that which defines group membership, may be excluded.

Related Conditions & MeSH terms

• Anxiety Disorder
• Anxiety Disorders
• Craniocerebral Trauma
• Disease
• Head Injury
• Mood Disorder
• Mood Disorders
• Schizophrenia
• Seizures

Locations

Country	Name	City	State
France	Genethon	Every Cedex
Russian Federation	Mosco Research Institute of Psychiatry	Moscow
United States	National Institutes of Health Clinical Center, 9000 Rockville Pike	Bethesda	Maryland
United States	Henry Ford Health Systems	Detroit	Michigan
United States	Columbia University	New York	New York
United States	Mt. Sinai Medical Center	New York	New York
United States	Childrens National Medical Center	Washington, D.C.	District of Columbia

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Mental Health (NIMH)

Countries where clinical trial is conducted

United States,  France,  Russian Federation, 

References & Publications (1)

Johnstone EC, Owens DG, Bydder GM, Colter N, Crow TJ, Frith CD. The spectrum of structural brain changes in schizophrenia: age of onset as a predictor of cognitive and clinical impairments and their cerebral correlates. Psychol Med. 1989 Feb;19(1):91-103. — View Citation